Background 15 PRR14 (Proline rich protein 14) was firstly identified for its ability to specify and localize 16 heterochromatin during cell cycle progression. Aberrant expression of PRR14 is associated 17 with the tumorigenesis and progression of lung cancer. However, its involvement in colon 18 cancer remains unknown. Herein, we report the role of PRR14 in colon cancer.
RNA isolation and RT-PCR 110 Total RNA was isolated using RNA-simple Total RNA kit (DP419, Tiangen Biotech Co., 111 Beijing, China) according to the manufacturer's instructions. Reverse transcription was 112 done using ReverTra Ace qPCR RT kit (FSQ-101, Toyobo Co., Osaka, Japan). The PCR assay was performed using SYBR Green PCR Master Mix (QPK-212, Toyobo Co.) 114 on the CFX96 real-time PCR detection system (Bio-Rad, USA). The gene-specific primer 115 sequences are listed in Table 1 . GAPDH was used for quantitative internal referencing. The 116 2 -∆∆Ct method was used to analyze the results.
117 Table 1 . Genes-specific PCR primers. 118 Western blot 119 After 48h of siRNA transfection, the cells were collected and lysed with T-PER TM Tissue 120 Protein Extraction Reagent (Thermo Scientific, USA) containing protease inhibitor and 121 phosphatase inhibitor (Roche, Mannheim, Germany). The protein concentration was 122 determined with the BCA kit (Thermo Scientific). The western blot experiment was carried 123 out in accordance with the routine experimental steps. The following primary antibodies 124 were used: the rabbit anti-PRR14 antibody (1:500, HPA060265, Sigma, USA), rabbit anti-125 CDK2 antibody (1:1000, SAB4300388, Sigma), rabbit anti-P21 antibody and P27 antibody 126 (1:1000, 9932T, Cell Signaling technology, USA), rabbit anti-E cadherin antibody (1:200, 127 BM3903, Boster, China), rabbit anti-N cadherin antibody (1:500, RLT2988, Ruiying 128 Biological, China), mouse anti-vimentin antibody(1:500, 60330-1-IG, Proteintech, China), 129 rabbit anti-twist1 antibody (1:1000, SAB2108515, Sigma), rabbit anti-AKT antibody
130
(1:1000, 4691T, Cell Signaling technology), rabbit anti-phospho-AKT (Thr308) antibody 7
131
(1:1000, 13038T, Cell Signaling technology), rabbit anti-phospho-AKT (Ser473) antibody
132
(1:1000, 4060T, Cell Signaling technology), mouse anti-GAPDH antibody (1:1000, 133 AF0006, Beyotime, China). The secondary antibody used (goat anti-rabbit or goat anti-134 mouse secondary antibody) was conjugated to horseradish peroxidase (1:2000; Beyotime).
135
Chemiluminescence pictures were taken using the Super Signal Sensitivity Substrate Kit 136 (Pierce, Thermo Scientific) with the Chemi Doc XRS imaging system (Bio-Rad, USA).
137
Cell proliferation assay 138 Cell proliferation was measured using the CCK8 reagent (HY-k0301, MedChemExpress, 139 USA). Briefly, cells transfected with siRNA for 24 hours were counted and placed into 96-140 well plates with 1500 cells per well. 10µl of the CCK8 reagent was added into the cells at 141 0h, 24h, 48h, and 72h, respectively. The cells were incubated at 37 o C for 1h in a 142 humidified atmosphere of 5% CO 2 . Absorbance was measured at a wavelength of 450nm 143 by using the Varioskan Flash microplate reader (Thermo Scientific, USA).
144

Apoptosis analysis 145
Apoptosis detection was carried out using the FITC Annexin V Apoptosis Detection Kit 146 with PI (640914, Biolegend, USA). Cells were washed twice with cold BioLegend's Cell
147
Staining Buffer (Biolegend), and then resuspended in Annexin V Binding Buffer at a 148 concentration of 1.0 x10 6 cells/ml. 100µl of the cell suspension was transferred into a 1.5ml 149 test tube. 5µl of FITC Annexin V, followed by 10µl of Propidium Iodide Solution, was 150 added to the cell suspension. The cells were gently vortexed and incubated in the dark for 8 151 15min at room temperature. 400µl of Annexin V Binding Buffer was added to each tube.
152
The apoptotic samples were detected with flow cytometry (BD Biosciences, USA).
153
Tumor xenografts 154 After being transfected with siRNA for 48h, the HCT116 cells were digested and counted.
155 5 x 10 5 cells from the siNC and the siPRR14 groups were separately injected with insulin 156 syringe into the left and right dorsal flank of female nude mice, respectively. About a 157 month later, the mice were dissected, tumor samples were taken, and the length, width and 158 weight of the tumor were measured. The volume was calculated by using the modified 159 ellipsoid formula: volume =1/2 (length x width 2 ). Animal ethics was approved by the 160 Laboratory Animal Center of Chongqing Medical University.
161
Wound healing, migration and invasion assays 162
For wound healing assay, the cells were digested and counted. 1 x 10 6 cells were seeded 163 into each well of a 24-well plate, and incubated overnight. The cells were scratched in the 164 middle of the plate with white pipette tips, washed with PBS for 3 times to remove the 165 floating cells, and then photographed at 0h, 24h and 48h respectively. Transwell Chambers 166 with multiporous 8µm pore size PET membranes (MCEP24H48, Millipore, Germany) were 167 used for the migration and invasion assays. 2 x 10 5 cells were resuspended in 200µl serum-168 free medium and inoculated into the upper chamber. 500ml medium containing 10% FBS 169 was added into the lower chamber. The cells were incubated at 37 o C in a 170 humidified atmosphere of 5% CO 2 for 24h, and then fixed with polyformaldehyde for 171 20min. Thereafter, they were washed 3 times with PBS, stained with crystal violet for 9 172 10min, and washed 3 times with PBS. The cells in the upper chamber were then gently 173 wiped off with cotton swab, and the cells in the lower chamber were photographed.
174
Immunofluorescent assay 175 For phalloidin staining, cells were fixed with 4% paraformaldehyde for 20min, 176 permeabilized with 0.3% triton for 15min, and stained with TRITC-Phalloidin (40734ES75, 177 Yeasen, China) for 1h at room temperature. The nuclei were stained with DAPI for 10min, 178 and the Zeiss LSM 780 laser confocal microscope was used for photography.
179
Statistical analysis 180
Results are shown as mean ± SD. Statistical evaluation was performed with SPSS. The 181 student t test was used to determine differences between groups. The  2 test was used to 182 examine the relationship between the protein expression of PRR14 and the 183 clinicopathological factors. p < 0.05 was considered statistically significant.
184
Results
185
PRR14 is highly expressed in colon cancer; and this correlates with poor prognosis of 186 the disease. 187 Firstly, we used the GEPIA database to investigate the expression pattern of PRR14 in 188 colon cancer. The data showed that the mRNA expression of PRR14 was higher in the 189 cancer tissues than in the normal tissues. PRR14 expression was significantly correlated 190 with tumor grade ( Figure 1A and B ). The data from oncomine database also demonstrated a 191 higher expression of PRR14 in tumor tissues ( Figure 1C ). The TCGA survival data from 10 192 the human Protein Atlas database showed that higher PRR14 expression was associated 193 with worse patient outcomes ( Figure 1D ). We also evaluated PRR14 expression by using 194 tissue microarray from clinical patients. PRR14 positive signal was mainly detected in the 195 nucleus of non-neoplastic epithelium cells and tumor cells, and PRR14 staining was 196 obviously stronger in the cancer tissues than in the adjacent normal tissues ( Figure 1E Knockdown of PRR14 inhibited cell growth in vitro and in vivo. 217 To investigate the biological function of PRR14 in vitro, we knocked down PRR14 in two 218 colon cancer cell lines -HCT116 and RKO -via siRNA-mediated gene silencing. The 219 knockdown efficiency was determined by RT-PCR and western blot. The PCR results 220 showed that the two siRNAs had a knockdown effect on the mRNA levels (Figure 2A) , 221 while the western blot results showed that siRNA-2 had a better knockdown effect at the 222 protein level ( Figure 2B ). Therefore, siRNA-2 was selected for the following cell 223 experiments. 224 We analyzed the effect of PRR14 on colon cancer cell growth using the CCK8 assay. The 225 results showed that the cell proliferation rate was decreased in both HCT116 and RKO cells 226 after transfection with the PRR14 siRNA ( Figure 2C and D) . Meanwhile, PRR14 did not 227 affect the rate of apoptosis in both cell lines ( Figure S1 ). Furthermore, colony formation 228 assay showed that PRR14 knockdown significantly reduced the clonogenic ability of the 229 cells ( Figure 2E ). Subcutaneous tumorigenesis experiment showed that the tumor volume 230 and weight were significantly lower in the knockdown group than in the control group 231 ( Figure 2F and G) . These results show that PRR14 plays a role in the growth of colon 
240
Knockdown of PRR14 inhibited cell migration and invasion.
241
The scratch-wound assay and transwell assay were performed to assess the effects of 242 PRR14 on migration and invasion of HCT116 and RKO cells. The scratch assay showed 243 that the wound healing time in the PRR14 siRNA group was significantly slower than in 244 the control siRNA group ( Figure 3A) . The transwell experiment and matrigel coated 245 transwell experiment showed that the migration and invasion ability of the siRRR14-treated 246 cells were decreased ( Figure 3B and C) . This suggest a role of PRR14 in the migration and 247 invasion of colon cancer. Figure 4B ). By immunofluorescent labeling of actin filaments, we 259 found that the number of pseudopodia in the cells was significantly reduced ( Figure 4C ).
260
These results demonstrate that PRR14 may affect colon cancer metastasis by regulating 261 EMT and cytoskeletal remodeling. To clarify the mechanism by which PRR14 regulates the cell cycle, we knocked down 272 PRR14 and examined its effects on the expression of cell cycle regulatory genes.
273
Knockdown of PRR14 in HCT116 and RKO cells significantly inhibited CDK2 mRNA 14 274 expression and protein expression, (Figure 5A and B) . In HCT116 cells, the mRNA 275 expression of CDK1 and CDK2 were also found to be decreased while the mRNA 276 expression of CDK kinase inhibitors -P21Cip1 and P27kip1 -were found to be elevated 277 ( Figure 5A and B) . Knockdown of PRR14 inhibited the phosphorylation of AKT and its 278 downstream gene, mTOR ( Figure 4D) . These results suggest that PRR14 modulates the cell 279 cycle gene expression and acts on the AKT pathway during colon cancer progression. In this study, we found that PRR14 was significantly upregulated in colon cancer, and this 289 is consistent with the results of previous analysis of the TCGA database (9). PRR14 
304
Numerous evidences show that cell phenotype and movement are related to EMT. EMT is 305 considered to be a critical step in the process of metastasis in a variety of tumors (18, 19) , 306 including colon cancer (20) . It is a complicated process in which cells are transformed from 307 epithelial phenotype to mesenchymal phenotype, thus gaining migration ability. In this 308 study, silencing of PRR14 changed the cells' morphology, and decreased the expression of 309 Twist1, an important transcription factor in the EMT process, which mediates the inhibition 310 of E cadherin expression and the up-regulation of N cadherin expression. This indicates that 311 PRR14 is involved in the EMT process. Since the cytoskeleton enhances pseudopodia 312 formation during the motility of cancer cells (21-24), and PRR14 was found to regulate 313 cytoskeletal remodeling, it could be stated that PRR14 promotes the metastasis of colon 314 cancer cells by modulating the structure of the cytoskeleton.
315
The PI3K/AKT pathway is involved in the regulation of proliferation, apoptosis and 316 migration in many tumors, including colon cancer. We have shown that silencing PRR14 317 induced changes in p-AKT and p-mTOR levels, indicating that PRR14 acts on PI3K/AKT 318 pathway. This is consistent with observations made about lung cancer cells. It has been 16 319 reported that PRR14 activates the PI3K/AKT pathway by binding with the SH3 domain of 320 GRB2 (8). GRB2 is widely expressed in a variety of cells and participates in many cellular 321 functions by transducing the receptor tyrosine kinase (RTK) signaling pathway. The SH2 322 domain of GRB2 receives RTK signals on the cell membrane and mediates the signals to be 323 transmitted to the downstream RAS/MAPK and PI3K/AKT pathways (25) (26) (27) . A previous 324 study has shown that PRR14 functions in the nucleus to regulate the localization of 325 heterochromatin (3). How it binds to GRB2 in the cytoplasm, or whether it has other 326 variants involved in GRB2 binding in the cytoplasm, is worth studying. Apart from acting 327 on the PI3K pathway through GRB2, as to whether PRR14 has another mechanism through 328 which it regulates the development and progression of colon cancer, remains to be 329 determined. It has been reported that PRR14's proline-rich domain is involved in protein-330 protein interaction by binding to multiple domains (4, 5). This suggests that PRR14 may 331 interact with other unknown molecules in regulating colon cancer development and 332 progression, and the identification of these molecules is our next research direction.
333
Conclusion
334
PRR14 plays an important role in the development and progression of colon cancer, and is 335 a possible prognostic marker and therapeutic target for the disease. Further exploration to 336 elucidate its specific molecular mechanism is of great significance. 
